MDxHealth SA (NASDAQ:MDXH) Sees Significant Decrease in Short Interest

MDxHealth SA (NASDAQ:MDXH) was the target of a significant decrease in short interest in February. As of February 15th, there was short interest totalling 13,300 shares, a decrease of 22.7% from the January 31st total of 17,200 shares. Currently, 0.1% of the company’s stock are short sold. Based on an average trading volume of 121,000 shares, the days-to-cover ratio is currently 0.1 days.

Analyst Upgrades and Downgrades

Separately, Piper Sandler cut their target price on shares of MDxHealth from $8.00 to $6.00 and set an “overweight” rating on the stock in a research note on Thursday, November 7th.

MDxHealth Stock Down 6.0 %

MDxHealth stock opened at $1.71 on Tuesday. MDxHealth has a 1-year low of $1.55 and a 1-year high of $3.85. The firm has a market capitalization of $80.86 million, a price-to-earnings ratio of -1.13 and a beta of 1.34. The firm’s fifty day moving average price is $2.00 and its two-hundred day moving average price is $2.18. The company has a current ratio of 1.54, a quick ratio of 1.45 and a debt-to-equity ratio of 3.14.

MDxHealth (NASDAQ:MDXH) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.07. The firm had revenue of $24.74 million for the quarter, compared to analyst estimates of $22.67 million. MDxHealth had a negative net margin of 49.52% and a negative return on equity of 1,077.84%. On average, equities research analysts predict that MDxHealth will post -1.15 earnings per share for the current fiscal year.

Institutional Trading of MDxHealth

Several institutional investors and hedge funds have recently made changes to their positions in MDXH. Geode Capital Management LLC purchased a new stake in shares of MDxHealth in the fourth quarter valued at about $25,000. Oppenheimer & Co. Inc. increased its holdings in MDxHealth by 100.0% during the fourth quarter. Oppenheimer & Co. Inc. now owns 20,000 shares of the company’s stock worth $47,000 after buying an additional 10,000 shares during the last quarter. FAS Wealth Partners Inc. increased its holdings in MDxHealth by 49.6% during the fourth quarter. FAS Wealth Partners Inc. now owns 24,425 shares of the company’s stock worth $58,000 after buying an additional 8,100 shares during the last quarter. XTX Topco Ltd purchased a new stake in MDxHealth during the fourth quarter worth about $63,000. Finally, Delta Investment Management LLC purchased a new stake in MDxHealth during the fourth quarter worth about $81,000.

MDxHealth Company Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.